NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Assessment of zidovudine therapy and concurrent opiate use.

MacCallum LR, Flegg PJ, Willocks LJ, Jones ME, Cowan FM, Brettle RP; International Conference on AIDS.

Int Conf AIDS. 1990 Jun 20-23; 6: 196 (abstract no. S.B.440).

Infectious Diseases Unit, City Hospital, Edinburgh, Scotland, U.K.

OBJECTIVE: Since prior research had indicated that opiates alter the pharmacokinetics of Zidovudine, we wished to assess the outcome of concurrent opiate use on Zidovudine therapy. RESULTS: We have treated 100 patients with Zidovudine at the Infectious Diseases Unit over 2.5 years commencing in July 1987. They were grouped as follows - 30 homosexuals, 66 IDUs and 4 of other risk groups. In the IDU group, 10 stopped treatment themselves because of side effects. All reported nausea some with associated headaches and dizzy spells. Fifty-six were then assessed on Zidovudine therapy, 39 of whom were concurrently using opiates. Progression, while on therapy, occurred in 13 patients. There were 3 deaths within the group, 1 incidental and 2 AIDS related. Opiate use continued in 10/13 including the 3 deaths. Forty-three had no evidence of progression and 29 of these continued with opiate usage. Marrow toxicity was recorded in 17 patients, 13 becoming transfusion dependent and 4 with episodes of neutropenia alone. Opiates were taken by 13/17. Of the 39 with no marrow problems, 26 continued on opiates. There is no statistical significance with intercurrent opiate use on either progression, marrow toxicity or transfusion requirements. CONCLUSION: Although pharmacokinetic studies show potentiation of Zidovudine levels in patients currently using opiates we have, so far, not encountered any statistically significant increases in toxicity or a change in the rate of progression in those who continue to use opiates while on Zidovudine therapy. There is therefore no contra-indication to initiating Zidovudine therapy in the presence of opiates.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Disease Progression
  • Drug Therapy, Combination
  • Humans
  • Narcotics
  • Neutropenia
  • Substance-Related Disorders
  • Zidovudine
  • drug therapy
  • methods
  • therapy
Other ID:
  • 30044090
UI: 102196252

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov